Diminishing the National Cancer Institute Threatens Americans
In an effort to reduce the size of government, the current administration has proposed an across the board 37% reduction1 in funding for the National Cancer Institute (NCI). This will result in approval of only 4% of applications2 from scientists at universities and cancer centers, with 96% of all new research proposals being rejected, the termination of some existing programs, and reduction in essential clinical trials.3
Axicabtagene Ciloleucel in Relapsed or Refractory Indolent Non-Hodgkin Lymphoma: 5-Year Follow-up of ZUMA-5
As reported in the Journal of Clinical Oncology by Neelapu et al, the 5-year follow-up of the phase II ZUMA-5 trial has shown sustained responses with axicabtagene ciloleucel (axi-cel) in patients with relapsed or refractory indolent non-Hodgkin lymphoma.
$16 Million PRISM Trial Will Explore AI in Breast Cancer Screening
The University of California, Los Angeles (UCLA) and UC Davis will co-lead a newly funded, multi-institutional clinical trial to evaluate whether artificial intelligence (AI) can help support radiologists in interpreting mammograms more accurately, with the goal of improving breast cancer screening and reducing unnecessary callbacks and anxiety for patients.
Zanzalintinib Plus Atezolizumab vs Regorafenib in Previously Treated Metastatic Colorectal Cancer Without MSI-H or dMMR Tumors
In a phase III trial (STELLAR-303) reported in The Lancet, Hecht et al found that the combination of the multitargeted tyrosine kinase inhibitor zanzalintinib and atezolizumab improved overall survival vs regorafenib in patients with previously treated relapsed or refractory metastatic colorectal cancer without microsatellite instability–high (MSI-H) or mismatch repair–deficient (dMMR) tumors.
Malignant Melanoma: Addition of Whole-Body Imaging in Postsurgery Follow-up
In an interim analysis of a Swedish phase III study (TRIM) reported in The Lancet Oncology, Ladjevardi et al found no improvement in outcomes with the addition of whole-body imaging to physical examination in a follow-up of patients undergoing radical surgery for stage IIB-C or III cutaneous malignant melanoma.
Charles Bennett and colleagues: The Inflation Reduction Act and Ibrutinib
Derek Raghavan: How I Discuss the Current Political Chaos When Patients Ask Health-Related Questions About It
Narjust Florez and Coral Olazagasti: Silence Is Complicity
Robert Peter Gale: Therapy With a TKI for EGFR-Variant Lung Adenocarcinoma: Lessons From CML?
Raj Mohan on Kindness, Mercy, Empathy, Compassion: Are They Relevant in the Era of Robotics and AI?
Sponsored Content
SPONSORED BY LILLY MEDICAL AFFAIRS
Clinical Impact of Comprehensive Genomic Profiling in Early-Stage Non–Small Cell Lung Cancer
SPONSORED BY JOHNSON & JOHNSON
Evolving Treatment Landscape in First-Line EGFR-Mutant NSCLC: New Insights Into Combination TherapiesMore Top Stories
Armando E. Giuliano, MD, To Be Honored With 2025 William L. McGuire Memorial Lecture Award at SABCS
Armando E. Giuliano, MD Armando E. Giuliano, MD, will receive the William L. McGuire Memorial Lecture Award during the 2025 San Antonio Breast Cancer Symposium (SABCS). Dr. Giuliano is being recognized for his pioneering work on sentinel lymph node biopsy for patients with breast cancer, which ...
Survey Highlights Unmet Needs Among Young Women With Advanced Breast Cancer
Almost half of all women (48%) under the age of 40 who are living with advanced breast cancer have children under the age of 18, and 64% of these young patients also experience employment disruptions after they are diagnosed, according to findings from a survey conducted by the Young Survival...
The Consequences of Climate Change on Cancer Development and Patient Care
Robert A. Hiatt, MD, PhD In 2021, The ASCO Post had a wide-ranging discussion with Robert A. Hiatt, MD, PhD, Professor in the Department of Epidemiology and Biostatistics at the University of California, San Francisco (UCSF), and Associate Director of Population Sciences at UCSF Helen Diller...
ASCO and ONS Issue First Collaborative Guideline on Extravasation
ASCO and the Oncology Nursing Society (ONS) have released their first joint guideline on managing extravasation, an uncommon but potentially life-threatening complication of intravenous antineoplastic therapy.1 Extravasation occurs when an agent with tissue-damaging properties leaks from the...
Global Report Highlights Decade of Uneven Progress in Advanced Breast Cancer Care
ABC Global Alliance's landmark Advanced Breast Cancer Global Decade Report 2015–2025 was recently released and published in The Breast. The report highlights significant advancements made over the past decade that have transformed care for patients with advanced breast cancer, but also reveals gaps ...
Making Clinical Trials More Accessible: New Report Highlights Barriers and Solutions
Clinical trials remain out of reach for many Americans, with only 7% of patients with cancer participating in clinical trials, according to a new report from the American Society of Clinical Oncology’s (ASCO) State of Cancer Care in America series. Experts agree that access to trials is a key...
Model for Predicting Risk of Heart Failure or Cardiomyopathy After Breast Cancer Treatment
In a study reported in JAMA Oncology, Barac et al developed a risk prediction model for heart failure or cardiomyopathy (HF/CM) after breast cancer treatment. Study Details The aim of the study was to construct a model predicting the 10-year risk of developing HF/CM in women receiving systemic...
